ImmunoACT develops NexCAR19, India's first indigenous CAR-T cell therapy, which modifies a patient's T-cells to enhance their ability to target and eliminate B-cell cancers such as Acute Lymphoblastic Leukemia and Large B-cell Lymphomas. This therapy addresses the high relapse rates and lack of response to first-line treatments, aiming to improve overall survival outcomes for patients with limited treatment options.
Funding
$15.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
For patients with B-cell cancers like Acute Lymphoblastic Leukemia and Large B-cell Lymphomas, a significant percentage do not respond to initial treatments or experience relapse. These patients face limited options and poor overall survival outcomes.
Solution
ImmunoACT develops CAR-T cell therapies that enhance a patient's own T-cells to target and eliminate B-cell cancers. Their initial CAR-T cell therapy, NexCAR19 (Talicabtagene autoleucel), modifies T-cells using a lentiviral vector to express proteins that target specific cancer cells and boost anti-tumor activity. This personalized approach aims to improve overall and disease-free survival rates, offering a potential remission for patients with hematological malignancies. The therapy is designed to be more familiar to the human immune system, potentially limiting side effects and improving safety.
Target Audience
The primary audience includes patients with B-cell cancers such as Acute Lymphoblastic Leukemia and Large B-cell Lymphomas who have not responded to first-line therapies or have relapsed, as well as the healthcare providers who treat them.
Features
- Utilizes a lentiviral vector for T-cell modification to target specific cancers.
- Designed to enhance anti-tumor activity of modified T-cells.
- Personalized therapy tailored to each patient.
- Aims to limit side-effects and improve safety through design.